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Abstract
Determining what constitutes protective immunity to TB is critical for the development of improved diagnostics and
vaccines. The comparison of the immune system between contacts of TB patients, who later develop TB disease
(progressors), versus contacts who remain healthy (non-progressors), allows for identification of predictive markers of TB
disease. This study provides the first comprehensive analysis of the immune system of progressors and non-progressors
using a well-characterised TB case-contact (TBCC) platform in The Gambia, West Africa. 22 progressors and 31 non-
progressors were analysed at recruitment, 3 months and 18 months (time to progression: median[IQR] of 507[187–714]
days). Immunophenotyping of PBMC, plasma cytokine levels and RT-MLPA analysis of whole blood-derived RNA was
performed to capture key immune system parameters. At recruitment, progressors had lower PBMC proportions of CD4+ T
cells, NKT cells and B cells relative to non-progressors. Analysis of the plasma showed higher levels of IL-18 in progressors
compared to non-progressors and analysis of the RNA showed significantly lower gene expression of Bcl2 but higher CCR7
in progressors compared to non-progressors. This study shows several markers that may predict the onset of active TB at a
very early stage after infection. Once these markers have been validated in larger studies, they provide avenues to
prospectively identify people at risk of developing TB, a key issue in the testing of new TB vaccines.
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Introduction
Close to one-third of the world’s population is infected with
Mycobacterium tuberculosis (MTb), the causative agent of tuberculosis
(TB), with infection rates highest in poverty-stricken countries in
Africa and Asia [1]. The majority of infected persons remain
asymptomatically (latently) infected with the pathogen, while 10%
progress to active TB within their lifetime, resulting in 2 million
deaths per year [1]. A better understanding of what constitutes
protective immunity to TB is critical for development of improved
diagnostics, treatment protocols and vaccines.
The abundance of latently infected individuals world-wide
constitutes an extremely large reservoir which fuels TB reactiva-
tion and subsequent transmission. However, the relatively low
proportion of people that progress to active TB disease suggests
that natural immunity to MTb is the general rule, although this
also complicates evaluation of intervention studies. The majority
of TB biomarker studies to date have focused on differences
between subjects with active TB compared to latently infected
counterparts [2–5]. These have shown the unequivocal role of
CD4+ T cells and IFN-c production in TB immunity [2–5], yet do
not allow distinction between the underlying cause of progression
to active TB and the dynamics of immune changes leading to or
resulting from this progression. Other potential immune markers
for determining susceptibility or protection to TB, including T cell
and B cell subsets [6], type I IFN signalling pathway [7] and
apoptotic and innate immune regulators [8] all need to be validated
in longitudinal cohort studies that monitor contacts of TB cases (TB
case-contact study (TBCC)) for TB disease progression [9]. One
such study in The Gambia followed 2348 contacts of TB cases for 2
years resulting in 26 progressors of which half were positive by TST
at recruitment and half were positive by ELISPOT [10]. Other
studies have examined the predictive values of IFN-c release assays
(IGRA) and TST responses at baseline but have also shown
inconclusive results [11,12]. Clearly, more complex immunological
parameters need to be assessed in order to determine more sensitive
bio-signatures of protection or susceptibility. This will not only aid
in development of effective TB vaccines but will ultimately reduce
TB transmission rates by enabling identification and early-
treatment of susceptible individuals.
This study provides the first detailed description of the immun-
ological differences between TB progressors and non-progressors at
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many months before the onset of disease. We compared plasma
cytokinelevels,peripheralbloodimmune cell phenotypesandwhole
blood RNA gene expression. These data provide an initial platform
for determining biomarkers of protective immunity to TB.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethical approval was obtained from
the Gambia Government/Medical Research Council Joint Ethics
Committee. All patients provided written informed consent for the
collection of samples and subsequent analysis.
The Gambian Tuberculosis Case Contact Study
In the TBCC study, we followed 317 adult sputum smear and
culture positivetuberculosisindex casesand2348 oftheir household
contacts. Participants were recruited between September 2002 and
September 2004. Household members were eligible for inclusion in
the study if they had been sleeping in the same compound (walled
group of houses) as the index case during the index case’s period of
illness with TB. All contacts underwent a clinical assessment and
had a Tuberculin Skin Test (TST: 2 tuberculin units (TU) of
Purified Protein Derivative (PPD) RT23, Staten Serum Institute,
Denmark) using the Mantoux technique. Subjects with skin test
induration of $10 mm diameter were categorised as TST positive.
Those with a negative TST at baseline had a repeat test after 3
months.
Follow-up
Study participants were followed formally for 2 years and
passively after that. Each individual was re-evaluated for symptoms
of tuberculosis at each visit. All TB suspects received a chest
radiograph and sputumanalysisforacid fast bacilli (AFB)smear and
culture. If tuberculosis disease was bacteriologically confirmed,
patients were referred for the standard six month tuberculosis
treatment course. Blood samples were taken at 3 months and 18
months following the initial visit and were processed to obtain
Peripheral blood mononuclear cells (PBMC), plasma and RNA
which were cryopreserved until required. Subjects were included if
they were .18 years of age and were HIV-1 sero-negative. Ethical
approval was obtained from the Gambia Government/Medical
Research Council joint ethics committee.
Study group definitions
All contacts with symptoms consistent with TB, that com-
menced at least 3 months after their respective index case was
diagnosed, were considered to be possible secondary TB cases
(termed progressor throughout this paper). A TB diagnosis was
based on chest x-ray and positive sputum smear and culture
results, and/or their response to TB treatment. Randomly chosen
non-progressors were age and sex-matched to the progressors and
were diagnosed as definitely not having TB for the whole follow-
up period. Non-progressors were selected from different household
as the progressors to reduce effects of clustering.
PBMC thawing and flow cytometry
PBMC were removed from liquid nitrogen and semi-thawed in
a3 7 uC water bath. They were then quickly resuspended in cold
RPMI+10%FCS and centrifuged (1500 rpm, 5 min), followed by
a second wash to remove residual DMSO. Cells were then
resuspended in RPMI+10% FCS and counted. For flow cytometry
staining, at least 200,000 cells were used per test. After carefully
removing the supernatant, 20 mL of previously titrated antibody
cocktail was added to each tube and vortexed. Cells were then
incubated at 4uC for 15 min, followed by a wash with cold PBS/
FCS/Azide buffer. Supernatant was removed and cells resus-
pended in 1% paraformaldehyde for flow cytometry acquisition.
Antibodies used were CD4-PerCP, CD8-Pacific Blue, CD27-APC,
CD45RO-PE, CD56-PE, CD56-PECy7 (all from BDPharmingen,
USA); CD3-PE-Cy7, CD19-APCAlexa750 (all from eBioscience,
UK) and Va24-FITC and Vb11-PE (Beckman Coulter, USA). All
samples were acquired with a 9-colour (11-parameter) CyAn ADP
TM
flow cytometer (Beckman Coulter, USA). Prior to acquisition,
calibration and compensation were performed and lymphocytes
gated according to 90u forward and side scatter plots. FACS plots
were analysed using FlowJo software (Treestar, OR), version 6.1.1.
Multiplex cytokine analysis of plasma samples
Plasma samples from TB cases, non-progressors and progressors
at recruitment, 3 months and 18 month time-points were analysed
using a Bio-Rad custom made 7-plex kit according to the manu-
facturer’s instructions. Cytokines assessed were: IL-10, IL-12(p40),
IL-13, IL-17, IL-18, IFN-c and TNF-a. Following pre-wetting of
the filter plate, 50 ml of bead suspension was added to each well
and washed twice. 50 ml of samples and standards were then added,
the plate was sealed and shaken for 30 sec at 1100 rpm, and
incubated for 1 hr at 300 rpm. The plate was washed 3 times then
25 ml of pre-diluted detection antibody was added. Following
shaking,theplate wasincubated for30 min. at 300 rpminthe dark.
After washing, 50 mlo f1 6 streptavidin-PE was added to each
well and incubated for 10 min. The plate was again washed and
resuspended in 125 ml of assay buffer, sealed, mixed and immediately
read on the Bioplex analyser using Bioplex manager software
(version 4.0; Bio-Rad, USA) and a low PMT setting. All standards
were run in duplicate.
Dual-colour Reverse Transcription Multiplex
Ligation-dependent Probe Amplification (RT-MLPA)
RNA was isolated at MRC Unit, The Gambia from peripheral
blood using Paxgene tubes and extraction kits according to the
manufacturer’s instructions (Qiagen) and shipped to Leiden Uni-
versity Medical Center (LUMC). Dual colour RT-MLPA was
performed at LUMC [13,14] with several major modifications [15],
including probe-primer design for 45 genes of interest [15,16].
Briefly, 100–150 ng RNA was reverse transcribed using gene-
specific RT primers and MMLV reverse transcriptase. This was
denatured and hybridized overnight at 60uC with a SALSA probe
mix (MRC Holland, The Netherlands). After treating the samples
with ligase-65 (MRC-Holland, The Netherlands) for 15 min at
54uC, PCR amplification was performed with specific SALSA
FAM- or HEX-labelled MAPH primers (2 mM each, forward
primer 59-GGCCGCGGGAATTCGATT-39 and reverse primer
59-GCCGCGAATTCACTAGTG-39), 13.75 mLH 20 and 0.25 mL
SALSA polymerase [15]. PCR conditions were 33 cycles of 30 s at
95uC, 30 s at 58uC and 60 s at 72uC, followed by 1 cycle of 20 min
at 72uC. PCR products were then diluted 1:10 in HiDi formamide
containing 400 HD ROX size standards and analysed on an ABI
PRISM 3730 capillary sequencer (Applied Biosystems, UK). Data
were analysed using GeneMapper software (Applied Biosystems,
UK) and peak areas were exported to a Microsoft Excel file.
Sample-related and peak-related differences in PCR and electro-
phoresis efficiency were corrected by adjusting to GAPDH
housekeeping gene. Signals below the threshold value for noise
cut-off (peak area #200) were adjusted accordingly. A positive
control that encompassed the combined target-specific sequences of
the left and right hand half-probes was used for all runs.
TB Biomarkers
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For Hematological, Immunophenotyping and Luminex analy-
ses, group medians and distributions were compared using a
Kruskal-Wallis test followed by Dunn’s post-test comparison. For
RT-MLPA analysis a Mann-Whitney U-test was performed. To
avoid the assumption of constant variance within groups, robust
variance estimates were used. Analyses were performed using
STATA version 9.1 (Stata Corporation, USA) and Matlab version
7.6 (Mathworks, Natwick, 2008).
Results
Subject information
We analysed 22 confirmed TB progressors. These had PBMC
and/or RNA and/or plasma samples available but not all sample
types were available for all subjects at all time-points. Of the
progressors, 14 had viable PBMCs stored at recruitment, 9 at 3
months and 9 at 18 months. These were matched with 31 non-
progressors at recruitment, 35 non-progressors at 3 months and 22
non-progressors at 18 months. For cytokine levels within plasma
samples, 13 progressors were analysed at each time-point and
compared to 21 non-progressors. For RT-MLPA analysis, 12
progressors and 31 non-progressors were analysed. The media-
n[IQR] age of the confirmed progressors was 25[20–45] with 58%
males. The non-progressors were age and sex matched. To try and
correct for the variation in the time taken to progress to active
disease (median[IQR] of 507[187–714] days), we performed
analyses based on early (progression between 90–507 days) versus
late (progression .507 days) progressors where possible (indicated).
Comparison of hematological parameters between
progressors and non-progressors
There were no significant differences between progressors and
non-progressors at any time-point for any of the hematological
parameters analysed (WBC, Hemoglobin, MCV and platelets)
(Fig. 1; Table 1). However, Hemoglobin levels were significantly
increased at the 18 month time-point compared to recruitment for
the progressors (median[IQR]=15.3[14.4–16.7] and 12.1[11.6–
14] respectively; p,0.01, Fig. 1A). When the progressors at
recruitment were analysed based on those progressing early
(,median time-point of 507 days; EP) compared to those pro-
gressing late (.median time-point of 507 days; LP), there was a
significantly lower level of MCV in EP compared to LP (median
[IQR]=82[78–88]and88[81–90]respectively;p=0.043;Table1).
Comparison of lymphocyte subsets between progressors
and non-progressors
Lymphocyte populations were gated according to FSC and SSC
profile (Fig. 2A) and analysed for specific subsets (CD4+, CD8+
and NKT cell populations are shown (Fig. 2A). Analysis at
recruitment showed a significantly lower level of CD4+ T cells
from progressors compared to non-progressors (median[IQR]=
21[17–34] and 30[22–37] respectively; however this was not seen
at the other time-points (Fig. 2C, Table 1). B cells were significantly
Figure 1. Analysis of hematological parameters in progressors versus non-progressors. Hemoglobin (A) and MCV (B) levels, Total white
blood cell (WBC) (C), and platelet (D) counts, were obtained from the Hematology lab at MRC, Fajara. Bar indicates median of 13 progressors and 28
non-progressors at recruitment (0), 9 progressors and 30 non-progressors at 3-months (3) and 7 progressors and 19 non-progressors at 18 months
(18). Data were analysed using a Kruskal-Wallis test followed by Dunn’s post-test comparison. Significant differences are indicated.
doi:10.1371/journal.pone.0025230.g001
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(p=0.001; Fig. 2F, Table 1) but were relatively low at the
recruitmenttime-pointandwerecomparabletothe non-progressors
at 18 months. In progressors we also found a significantly lower
frequency of Va24+Vb11+ NKT cells (median[IQR]=0.06[0.05–
0.11]; p,0.05) but a significantly higher level of CD4+CD25+ cells
(median[IQR]=1.5[1.0–1.9]; p,0.05) at recruitment compared to
non-progressors (median[IQR]=0.09[0.05–0.33] and 1.1[0.7–1.4]
respectively; Figs. 3A and 3C; Table 1). However, no differences in
T regulatory (CD4+CD25+CD127
lo) cell frequency was observed,
indicating that the CD4+CD25+ cells were most likely activated
T cells. While we saw a trend towards a higher proportion of
CD45RO+CD27+ (central memory) and lower levels of
CD45RO2CD272 (terminal effector) cells in both the CD4+
and CD8+ subsets for progressors, these were not significantly
different from non-progressors at any time-point (Table 1).
However, we did see a significant decrease in the proportion of
terminal effector cells within the CD4+ subset at 3 and 18 months
compared to the recruitment time-pointfor the progressors (p,0.05
for both; data not shown). The only other subset that showed a
difference between recruitment and 18 month time-points for the
progressors were CD4+CD127+ cells (%) which were significantly
higher at 18 months (p,0.01; Fig. 3F). We also compared early to
late progressors at the recruitment time-point and found that CD4+
T cells were significantly lower in EP compared to LP (media-
n[IQR]=19[11–32] and 24[18–42] respectively; p=0.029;
Table 1) and also compared to the non-progressors (p=0.002).
Indeed, there were no significant differences between the LP and
the non-progressors for any lymphocyte subset evaluated (Table 1).
The lower proportion of NKT cells from progressors at the
recruitment time-point was also due to a significant difference
between non-progressors and the early progressors (median[IQR]
=0.09[0.05–0.33] and 0.08[0.05–0.13] respectively; p=0.011;
Table 1).
Comparison of plasma cytokine levels in progressors and
non-progressors
Analysis of ex-vivo plasma cytokine levels showed very low
levels in all samples. IL-18 was detectable at the highest level for all
groups and was significantly higher in progressors at all time-
points compared to non-progressors (median[IQR]=89[68–120],
99[55–147], 120[42–180] and 20[5–36] respectively; p,0.001 for
all; Fig. 4A). No significant differences were observed for any other
cytokine, presumably due to the low levels in all samples.
However, the proportion of non-progressors with detectable levels
of IFN-c was higher than in the progressors at all time-points
(Fig. 4B).
Gene expression differences between progressors and
non-progressors
We used RT-MLPA to detect differences in expression of
specific genes between progressors and non-progressors. We saw a
Table 1. Hematological and Immunological peripheral blood analysis: comparison of non-progressors with total progressors, early
progressors and late progressors at the recruitment time-point.
Subset Early Progressors Late Progressors Total Progressors Non-Progressors
Hemoglobin (g/dL) 13[11–14] 12[12–15] 12[12–14] 13[12–14]
WBC (610
9/L) 4.2[3.9–4.8] 6.1[3.9–6.6] 4.5[3.9–6.1] 5.1[4.4–7]
MCV (fL) 82[78–88] 88[81–90] 85[80–90] 84[80–89]
Platelets (610
9/L) 244[196–299] 217[141–286] 237[169–283] 215[184–237]
% CD3 52[38–61] 52[35–62] 52[35–60] 54[48–62]
% CD4 19[11–32]* 24[18–42] 21[17–34]* 30[22–37]
% CD8 17[10–31] 16[9–18] 16[10–22] 16[13–20]
% B CELLS 6.5[3–11] 8[6–10] 6.5[5–10] 11[8–16]
% NK CELLS 9.2[9–16] 13[8–21] 11.1[9–17] 12[6–19]
% NKT CELLS 0.08[0.05–0.13]* 0.06[0.02–0.09] 0.06[0.05–0.11]* 0.09[0.05–0.33]
% cd T CELLS 7.3[3.8–14.6] 5.4[2.3–8.5] 7.3[2.5–11] 6.9[4.3–10.4]
% CD4
+CD25




lo 0.6[0.4–1.1] 0.7[0.4–0.9] 0.6[0.4–0.9] 0.6[0.3–0.9]
% CD4
+IL7R
+ 67[47–89] 80[78–91] 79[67–89] 80[72–88]
%CD8
+IL7R
+ 47[26–54] 46[32–65] 46[32–59] 54[41–61]
%CD4
+ NAI ¨VE 37[17–46] 39[27–59] 38[25–51] 35[21–43]
%CD4
+ CM 32[29–43] 33[23–44] 32[27–40] 32[27–45]
%CD4
+ EM 19[14–32] 16[11–29] 19[12–26] 18[14–27]
%CD4
+ TE 10[8–14] 5[4–7] 7[5–10] 6[2.3–15]
%CD8
+ NAI ¨VE 49[24–55] 45[10–53] 46[15–53] 43[25–55]
%CD8
+ CM 15[9–18] 12[10–18] 13[10–18] 13[10–21]
%CD8
+ EM 8[4–16] 11[6–43] 9[6–28] 10[4–16]
%CD8
+ TE 33[25–48] 30[26–35] 31[26–38] 29[20–40]
Data expressed as median[interquartile range]. WBC=White Blood Cells; MCV=Mean Corpuscular Volume; Early Progressors (#507 days to progression); Late
Progressors (.507 days to progression); CM=central memory; EM=effector memory; TE=terminal effectors.
*=significantly different to non-progressors (please refer to text for actual p-values).
doi:10.1371/journal.pone.0025230.t001
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25230Figure 2. Percentage of T, B and NK cells in progressors and non-progressors. Cryopreserved PBMC were thawed and analysed.
Representative FACS plots indicating our gating strategy are shown in (A): following gating on the lymphocyte population as determined by the FSC/
SSC profile, we analysed lymphocyte populations. Shown are a representative CD4+ and CD8+ profile and a comparison of Va24+Vb11+ invariant
NKT cell levels in a progressor (left) and non-progressor. All subjects were analysed for percentages of total T cells (B), CD4+ (C), CD8+ (D), CD4:CD8
Ratio (E), B cells (F) and NK cells (G). Bars indicate median of 14 progressors and 31 non-progressors at recruitment (0), 9 progressors and 35 non-
progressors at 3 months (3) and 9 progressors and 22 non-progressors at 18 months (18). Data were analysed using a Kruskal-Wallis test followed by
Dunn’s post-test comparison. Significant differences are indicated.
doi:10.1371/journal.pone.0025230.g002
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[IQR]=2109[1616–2591] compared to non-progressors (2882
[2123–1353] respectively; p=0.011; Table 2). Conversely,
progressors had significantly higher levels of chemokine receptor
7 (CCR7) compared to non-progressors (median[IQR]=19126
[17384–21655] and 15849[14602–19971] respectively). Analysis
of the fold-differences between progressors and non-progressors
showed the highest fold-difference (2.51) for Bactericidal Perme-
ability Increasing gene (BPI) and the lowest for FCGR1A (0.57) in
progressors compared to non-progressors, although neither of
these were significant due to high standard deviations (Table 2).
Levels of b2-microglobulin were similar between the groups (data
not shown).
Discussion
This study provides the first detailed comparison of the immune
system between contacts of TB cases who progress to active disease
and those who don’t progress, thus increasing our knowledge of
what constitutes protective immunity in TB. The major differences
between progressors and non-progressors included a significantly
lower percentage of CD4+ T cells and NKT cells but significantly
higher percentage of CD4+CD25+ cells in progressors at
recruitment. We also found significantly higher plasma IL-18
levels and higher CCR7 but lower Bcl2 gene expression in
progressors compared to non-progressors. These differences
were generally due to early progressors: the immune system of
Figure 3. Percentage of NKT cells, cd T cells, T regulatory cells and CD127 expression in progressors and non-progressors.




lo cells (D), CD4+CD127+ cells (E) and CD8+CD127+ cells (F). Bars indicate median of 14 progressors and 31 non-progressors at
recruitment (0), 9 progressors and 35 non-progressors at 3 months (3) and 9 progressors and 22 non-progressors at 18 months (18). Data were
analysed using a Kruskal-Wallis test followed by Dunn’s post-test comparison. Significant differences are indicated.
doi:10.1371/journal.pone.0025230.g003
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recruitment time-point, whilst subjects who progressed between
90–507 days following recruitment showed the most immunolog-
ical differences to non-progressors.
While we found significant differences at the hematological,
lymphocyte, plasma and RNA levels, our analyses also raised
many limitations which can only be addressed in a much larger
cohort study such as the Gates Grand Challenge for TB [3].
Firstly, the number of progressors used in this study was small.
While this could be overcome in part by increasing the number of
non-progressor samples we analysed, it could not overcome the
fact that we had such variability in progression time. Secondly, the
interval between the 3 month and 18 month sample collection
time points did not facilitate a precise analysis of the changes in the
immune system prior to progression to active disease; which is
highlighted by the fact that the early-progressors showed the most
differences to the non-progressors. Future work should allow for
increased time-points of sample collection to ensure the immune
responses are captured at the closest possible time-point to
progression.
Despite these difficulties, there were several parameters that
showed differences between progressors and non-progressors and
Figure 4. Analysis of cytokine levels in the plasma of progressors and non-progressors. 7-plex Luminex analysis was performed on
cryopreserved plasma samples. Data shown are for IL-18 (A) and IFN-c (B). Bars indicate median of 13 progressors at recruitment, 3 and 18 months
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immunity to TB. Interestingly differences were observed in both
the innate and the adaptive immune systems, reinforcing the
requirements for triggering the innate immune response (through
use of adjuvants) in the design of new and improved vaccines [17].
At the RNA level, we saw the highest fold-difference in BPI and
the lowest fold-difference in FCGR1A (CD64) in progressors
compared to non-progressors; both of which are expressed by
neutrophils and are important in the control of bacterial infections
[18,19]. CD64 is important in the immune response to TB with
defects in this gene resulting in increased susceptibility to TB [19],
although recent work has shown subjects with active disease to
have significantly higher levels of this gene in comparison to
latently infected individuals [8]. IL-18 is produced by the innate
immune system, acts as a precursor to IFN-c production and is
highly increased in patients with advanced tuberculosis [20,21].
This suggests that the observed increase in plasma IL-18 levels in
progressors compared to non-progressors is important in the early
stages of the immune response to Mycobacterium tuberculosis
infection. No difference in NK cell proportion was observed at
any time-point but a significantly lower proportion of invariant
NKT cells were seen in progressors compared to non-progressors.
Invariant NKT cells act as a link between the innate and adaptive
immune systems and are important in the control of bacterial
infections [22,23], thus a reduction in NKT cell numbers will
invariably have downstream effects on the efficacy of the adaptive
immune response. The major difference in the adaptive immune
system was a significantly lower proportion of CD4+ T cells in
progressors compared to non-progressors. The crucial role of
CD4+ T cells in protection against TB disease progression is
supported by the profound increase in TB associated with HIV-
induced CD4 depletion [24]. The decrease in CD4+ T cells in
progressors may be associated with the decreased levels of the anti-
apoptotic gene, Bcl2 that we observed. The role of apoptosis in
Table 2. Differences in RT-MLPA gene expression levels in progressors and non-progressors.
Description Variable Non-Progressors Progressors Fold difference
apoptotic factors BCL2 2882[2123–3338] 2109[1616–2591] 0.73
Caspase8 12034[10076–14078] 10960[8272–13771] 0.91
TNFRSF1A 13682[11793–15626] 14396[10648–17683] 1.05
TNFRSF1B 3656[3249–4180] 4124[3790–4620] 1.13
Cytokines/chemokines TNF 200[200–1392] 200[200–1874] 1.00
BLR1 1443[1035–1777] 1734[1273–2190] 1.20
CXCL10 200[200–386] 271[200–746] 1.36
CCL19 565[308–735] 537[200–650] 0.95
CCL22 276[200–664] 375[200–695] 1.36
CCL4 200[200–261] 200[200–200] 1.00
CCR7 15849[14602–19971] 19307[17648–22192] 1.22
Innate immunity CD163 1224[1144–1518] 1251[1154–1752] 1.02
FPR1 14203[11336–19155] 13540[10369–20923] 0.95
LTF 200[200–200] 200[200–200] 1.00
BPI 518[200–1677] 1300[281–2055] 2.51
NCAM1 1850[1532–2374] 1617[1345–2258] 0.87
B cell factors CD19 597[249–946] 664[497–874] 1.11
FCGR1A 883[310–1270] 505[200–1811] 0.57
MMP9 200[200–539] 280[200–594] 1.40
TIMP2 15285[12874–16946] 17429[13864–20035] 1.14
T cell factors CD3e 21509[17293–25332] 21207[19301–22977] 0.99
CD4 4165[3440–5119] 4880[3333–7075] 1.17
CD8a 200[200–2560] 200[200–4699] 1.00
IL7R 16796[13231–21510] 16048[13606–18574] 0.96
Regulatory T cells CTLA4 200[200–436] 200[200–309] 1.00
FOXP3 245[200–434] 235[200–475] 0.96
TGFB1 5211[4616–5811] 5420[4579–6268] 1.04
TGFBR2 5745[5114–6523] 6161[4583–7252] 1.07
Intracellular trafficking RAB13 1073[396–1189] 1082[746–1384] 1.01
RAB24 2229[1976–3125] 2678[2275–3096] 1.20
Rab33A 200[200–287] 219[200–318] 1.10
SEC14L1 15727[13077–19137] 18310[15395–26280] 1.16
Data expressed as median[interquartile range]. Fold difference is shown as expression in progressors compared to non-progressors. BPI showed the highest fold
increase and FCGR1A the lowest.
doi:10.1371/journal.pone.0025230.t002
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25230protection against TB disease is complicated as there are
differential effects depending on the cell type involved. For
instance, induction of apoptosis of infected macrophages is crucial
for control of disease [25] and is induced by TNF-a [26]. It is
thought this allows removal of infected cells while minimizing
tissue destruction in adjacent, uninfected cells [27]. Conversely,
apoptosis of T cells is detrimental to control of disease progression
[25]. Thus, further studies should separate cells into monocytes
and lymphocyte subsets in order to identify which cells are affected
by the reduced Bcl2 expression. Indeed, a recent study which
separated lymphocytes from monocytes prior to RT-MLPA,
showed differential levels of Bcl2 in patients with sepsis compared
to controls in the lymphocyte but not monocyte populations [28].
In conclusion, this study provides the basis for further
exploration of protective immunity to TB using a case-contact
study platform and nested case-control study. Our findings suggest
that several markers may predict the onset of active TB in exposed
asymptomatic household contacts. These markers, once validated
in a larger cohort study, may help to prospectively identify patients
at risk of developing active TB as well as demonstrating natural
protective immune requirements for the next generation of TB
vaccines. Once these markers have been validated in larger
studies, they provide avenues to prospectively identify people at
risk of developing TB, a key issue in the testing of new TB vaccines
[29].
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